Navigation Links
Ellex Commences Direct Sales in Germany
Date:9/10/2008

ADELAIDE, Australia, Sept. 10 /PRNewswire/ -- Ellex Medical Lasers Limited (ASX: ELX) today announced another step in expanding its global reach with the establishment of a direct sales channel in Germany -- Ellex Deutschland GmbH.

To be formally launched at the European Society of Cataract and Refractive Surgeons (ESCRS) meeting in Berlin, 13-16 September 2008, Ellex Deutschland GmbH will focus initially on sales of Ellex laser products. Ellex's distribution partner for the Eye Cubed ultrasound product in Germany, M+C GmbH, will provide administration and logistical support for the new operations, allowing Ellex to establish a strong market position with minimal investment and reduced risk.

M+C have been active in the ophthalmic market for 20 years and have distributed the Eye Cubed since 1990. Their excellent reputation and strong sales and marketing network will be a significant benefit in establishing Ellex quickly in the German market. The partnership between Ellex and M+C will enable both companies to leverage common marketing channels and contacts. Plans include joint exhibits at German trade shows, promotional campaigns and educational workshops.

With over 8,000 ophthalmologists, Germany is one of the largest ophthalmic markets in the world. "The German market has significant potential and we look forward to working directly with ophthalmic surgeons throughout the region to demonstrate the quality of our products and our commitment to service. We are fortunate to have attracted experienced sales and service staff, and have the benefit of partnering with M+C, who have been our leading Eye Cubed distributor for many years," commented CEO Mr. Kevin McGuinness.

The first sales from the German operation are expected in September 2008. Ellex Deutschland GmbH will participate in its first official exhibition during the 2008 congress of the Deutsche Ophthalmologische Gesellschaft (DOG), which takes place immediately following the ESCRS in Berlin. The DOG is attended by more than 3,000 ophthalmologists and staff.

ABOUT ELLEX

Ellex Medical Lasers Limited (ASX: ELX) designs, manufactures and markets a complete line of lasers and diagnostic ultrasound systems used by ophthalmologists to diagnose and treat eye diseases. With more than 14,000 systems delivered to the market, Ellex has evolved since 1985 from a manufacturing company of primarily OEM products, to direct marketing of its own branded products through subsidiaries in the United States, Japan and Australia, and a network of distribution partners in more than 100 countries. In December 2006 Ellex acquired Innovative Imaging, a leading provider of diagnostic ultrasound devices for ophthalmology, initiating the expansion of its product line beyond lasers. Ellex maintains a strong emphasis on intellectual property and research into new and better treatments to manage and treat the leading causes of blindness.

For additional information about Ellex and its products, please visit http://www.ellex.com.


'/>"/>
SOURCE Ellex Medical Lasers Limited
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Ellex Announces New Retina Regeneration Therapy to be Presented at the AAO
2. MDS Commences Arbitration against AECL over Cancelled MAPLE Project and Files $1.6 Billion Court Claim against AECL and the Government of Canada
3. Sun Pharma Commences All Cash Tender Offer to Purchase Taro Ordinary Shares for USD 7.75 Per Share
4. uKarma Corporation Commences International Distribution Agreement With Northern Response for its Xflowsion DVD Series
5. UltraShape(R) Commences Pivotal Study for First Non-Invasive Fat Reduction and Body Contouring Device Using Non-Thermal Selective Focused Ultrasound
6. China Sky One Medical, Inc. Commences Trading on the American Stock Exchange
7. Takeda Commences Cash Tender Offer for all Outstanding Shares of Millennium
8. SXC Health Solutions Corp. Commences Exchange Offer For Shares Of National Medical Health Card Systems, Inc.
9. Reckitt Benckiser Commences Cash Tender Offer for All Outstanding Shares of Adams Respiratory Therapeutics
10. Cytopia Commences Phase II Cancer Drug Study
11. Amarin Commences First Clinical Trial in Cardiovascular ProgramAmarin Commences First Clinical Trial in Cardiovascular Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... National recruitment ... a life sciences executive with extensive sequencing and genomics experience, as Vice President of ... position, Ms. Hill will be responsible for leading the sales team in the commercialization ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, MTI-GlobalStem, a provider ... and other difficult to transfect cells, announces its launch of the PluriQ™ G9™ ... Editing System is a complete system for culturing and transfecting human pluripotent ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Finally, a bruise ... venous procedures, dermaka cream can be incorporated into the post-surgical treatment plans of a ... procedures. , dermaka cream is very effective for bruising and causes a rapid ...
(Date:6/24/2016)... ... 24, 2016 , ... Southern Illinois University School of Dental ... Illinois State Dental Society (ISDS) Foundation’s Mission of Mercy (MOM). They will host ... Collinsville. , They expect to treat approximately 2,000 patients from Illinois, ...
(Date:6/24/2016)... ... June 24, 2016 , ... SpiritQuest Sedona Retreats, located in Arizona ... surrounded by famous vortex sites: Cathedral Rock, Airport Mesa, and Boynton Canyon. The new ... Lodge at Sedona as well as the Sedona Rouge, both popular accommodations for SpiritQuest ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... and INDIANAPOLIS , June 23, ... a Lilly Diabetes Tomorrow,s Leaders Scholarship is any indication, ... winners, announced today online at www.diabetesscholars.org by ... 1 diabetes stand in the way of academic and ... the Foundation,s scholarship program since 2012, and continues to ...
Breaking Medicine Technology: